Sign up for email updates
Bookstore

Arthritis

Back Pain & Osteoporosis
Coronary Heart Disease
Depression & Anxiety
Diabetes
Digestive Disorders
Heart Attack Prevention
Hypertension & Stroke
Lung Disorders
Memory
Nutrition & Weight Control
Prostate Disorders
Vision


Depression & Anxiety

From the Current Issue

New Research
No Increased Suicide Risk Seen With SSRIs

Suicide risk among patients taking selective serotonin reuptake inhibitors (SSRIs) or tricyclics is not significantly different, a new study shows.

The investigation, which used a British database including 3 million people, was conducted to examine the relationship between the use of SSRIs and suicidal thoughts and attempts. Anecdotal evidence has linked the drugs to suicidal behavior, especially among teens.

The researchers compared 2,062 nonsuicidal patients who were prescribed the tricyclics amitriptyline (Elavil) or dothiepin (available in the United Kingdom) or the SSRIs fluoxetine (Prozac) or paroxetine (Paxil) to 555 patients who experienced suicidal thoughts or behaviors for the first time after being prescribed one of the drugs.

Although there was no significant difference in the risk of suicidal behavior among patients on tricyclics and SSRIs, the risk of suicidal behavior was increased during the first month of starting any of the drugs, particularly in the first one to nine days.

The most likely explanation for the increased risk, the researchers say, is the fact that the drugs can take several weeks to begin working. It is also possible, but not as likely, that the drugs themselves initially worsened depression.


Journal of the American
Medical Association
Volume 292, page 338
July 21, 2004


 


Buy now

2005
WHITE PAPERS
Depression & Anxiety

The Depression and Anxiety White Paper from The Johns Hopkins White Papers series is an annual, in-depth report written by Hopkins physicians.

 

 

    Contact us 
    © 2005 Medletter Associates, Inc.